bimagrumab
mAbexperimental
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B. — Wikipedia
Clinical trial activity
18 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
14
Phase 3
3
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01433263)
Timeline
Indications
Studied for
- Cachexia · Phase 2
- Diabetes Mellitus, Type 2 · Phase 2
- Healthy Volunteers · Phase 1
- Hip Fractures · Phase 2
- Muscle, Skeletal · Phase 2
- Myositis · Phase 2/Phase 3
- Myositis, Inclusion Body · Phase 3
- Obesity · Phase 2
- Overweight · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Respiration, Artificial · Phase 2
- Sarcopenia · Phase 2
Mechanism of action
- Activin receptor type-2BANTAGONIST
ACVR2B antagonist
BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation.
- Activin receptor type-2BINHIBITOR
ACVR2B inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBimagrumab ↗
- ChEMBLCHEMBL3137353 ↗
Also known as
- bimagrumab
- bimagrumab
- bimagrumab
- bimagrumab
- bym338
- bym338
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07030127 | Phase 1 | Aug 11, 2025 | Eli Lilly |
| NCT06901349 | Phase 2 | May 23, 2025 | Eli Lilly |
| NCT06890611 | Phase 1 | Mar 25, 2025 | Eli Lilly |
| NCT06643728 | Phase 2 | Oct 21, 2024 | Eli Lilly |
| NCT05933499 | Phase 2 | Oct 1, 2023 | Harvard University |
| NCT05616013 | Phase 2 | Nov 16, 2022 | Eli Lilly, Versanis Bio, Inc. |
| NCT03005288 | Phase 2 | Feb 1, 2017 | Novartis, QPS |
| NCT02573467 | Phase 3 | Nov 2, 2015 | Novartis |
| NCT02468674 | Phase 2 | May 1, 2015 | Novartis |
| NCT02333331 | Phase 2 | Dec 9, 2014 | Novartis |
| NCT02152761 | Phase 2 | Sep 16, 2014 | Novartis |
| NCT01868685 | Phase 2 | Apr 1, 2014 | Novartis |
| NCT02250443 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2014 | Novartis |
| NCT01925209 | Phase 2/Phase 3 (Phase 3) | Sep 26, 2013 | Novartis |
| NCT01669174 | Phase 2 | Sep 1, 2012 | Novartis |
| NCT01601600 | Phase 2 | Jan 1, 2012 | Novartis |
| NCT01433263 | Phase 2 | Aug 1, 2011 | Novartis |
| NCT01423110 | Phase 2 | Aug 1, 2011 | Novartis |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 12 | 12 | 2 | 2011 |
| Eli Lilly | For profit | 5 | 5 | 2 | 2022 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| QPS | For profit | 1 | 0 | 1 | 2017 |
| Versanis Bio, Inc. | For profit | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1